Despite some share the concern of having their career plans delayed or disrupted by the pandemic, the new challenges emerged in these unprecedented times represent a unique opportunity to grow-up as oncology professionals and get ready to a new scenario where team working, humanisation of care and virtual education will be more crucial than ever.
The current evidence suggests that a large proportion of patients not responding to PD-1/PD-L1-targeted agents do not have PD-L1-expressing tumours
Lectures from this year’s ESMO awards recipients kick off the week leading up to the Education weekend of the ESMO Virtual Congress 2020
A key advance in the fight against cancer is the availability of multiple treatment modalities developed to target different aspects of tumourigenesis and maintenance of cancer
At ESMO Virtual Congress 2020, the first report of clinical responses in multiple solid tumour subtypes increases knowledge on safety of tumour-infiltrating lymphocyte-based adoptive cell therapy combined with immunotherapy.
Immunotherapy as second- and third-line treatment is effective in pre-treated malignant pleural mesothelioma
Presentations at ESMO Virtual Congress 2020 gave insights into the impact of COVID-19 on cancer management, cancer research and the healthcare professionals involved, which can help to prepare for future crises.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
